Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics develops targeted protein degradation medicines for immunological diseases as a clinical-stage biopharmaceutical company. News about KYMR commonly centers on oral small molecule degrader programs, including KT-621, a STAT6 degrader for Type 2 inflammatory diseases such as atopic dermatitis and asthma, and KT-579, an IRF5 degrader tied to inflammatory bowel disease biology.
Company updates also cover preclinical and clinical data presentations, FDA regulatory designations, collaboration activity involving degrader candidates such as KT-200, and periodic operating and financial results. Additional announcements include investor conference participation and shareholder voting matters.
Kymera Therapeutics (NASDAQ: KYMR) presented new preclinical data at EULAR 2022, showcasing the effectiveness of its investigational STAT3 degraders in blocking Th17 development and cytokine release, thereby preventing collagen-induced arthritis in a mouse model. The research confirms the potential of STAT3 targeting in treating autoimmune disorders, with significant suppression of pro-inflammatory cytokines observed. Kymera's STAT3 degrader, KT-333, currently in Phase 1 trials, is part of a broader strategy to address various immune-inflammatory diseases.
Kymera Therapeutics (NASDAQ: KYMR) presented significant data on its IRAK4 degrader KT-474 at the 2022 Society of Investigative Dermatology Annual Meeting. The findings indicated that KT-474 effectively degrades IRAK4 and inhibits cytokine production across various immune and skin cell types, supporting its potential for treating autoimmune diseases such as hidradenitis suppurativa (HS) and atopic dermatitis (AD). Notably, the Phase 1 clinical study demonstrated nearly complete IRAK4 degradation and cytokine inhibition in healthy volunteers, showcasing the drug's promise in inflammation-related conditions.
Kymera Therapeutics (NASDAQ: KYMR) revealed promising preclinical results at the AAI Annual Meeting 2022, highlighting the effectiveness of their novel protein degraders in treating inflammatory and autoimmune diseases. The data emphasized the advantages of IRAK4 and STAT3 degraders over traditional kinase inhibitors, demonstrating superior inhibition of immune signaling pathways and Th17 inflammation in animal models. These findings support further exploration into using these degraders for therapeutic applications in conditions like multiple sclerosis and rheumatoid arthritis, indicating significant clinical potential.
Kymera Therapeutics (NASDAQ: KYMR) reported key developments in its clinical programs and financial results for Q1 2022. The Phase 1 trial for IRAK4 degrader KT-474 has been amended to extend dosing from 14 to 28 days, allowing for enhanced efficacy evaluation. Clinical trials for STAT3 (KT-333) and IRAKIMiD (KT-413) oncology programs are underway. The company's cash balance stood at approximately $523 million as of March 31, 2022, providing a runway into 2025. Collaboration revenues were $9.6 million, down from $18.7 million in Q1 2021, while net loss increased to $36.7 million.
Kymera Therapeutics (NASDAQ: KYMR) will host its first quarterly call on May 3, 2022, at 8 AM ET to provide updates on its clinical-stage pipeline.
CEO Nello Mainolfi emphasized the commitment to transparency and stakeholder engagement following the company's IPO two years ago. The call will include financial results and program updates.
Kymera will also participate in multiple investor conferences through May, including the Bank of America Healthcare Conference and the UBS Global Healthcare Conference, showcasing its innovative drug development efforts.
Kymera Therapeutics (NASDAQ: KYMR) presented promising preclinical data on KT-253, a novel MDM2 degrader, at the AACR Annual Meeting 2022. KT-253 demonstrated superior potency, inhibiting tumor cell growth in the picomolar range, outperforming existing small molecule inhibitors (SMIs) by over 200-fold. In xenograft models for acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), a single low dose led to sustained tumor regression, highlighting its potential for improved efficacy in p53 wild-type tumors, which represent over 50% of malignancies. An IND is anticipated to be filed in 2022.
Kymera Therapeutics (NASDAQ: KYMR) announced participation in upcoming virtual investor conferences. Nello Mainolfi, PhD, Co-Founder, President, and CEO, will engage in fireside chats at:
- Cowen & Co. 42nd Annual Health Care Conference on March 8, 2022, at 9:50 a.m. ET
- Guggenheim Healthcare Talks on March 16, 2022, at 8:00 a.m. ET
Webcasts will be accessible in the Investors section of their website, with replays available for 90 days. Kymera is focused on targeted protein degradation to develop novel therapeutics for immune-inflammatory diseases and cancers.
Kymera Therapeutics reported significant progress in its clinical trials and financial results for 2021. The company completed dose escalation in the KT-474 Phase 1 trial, demonstrating near complete IRAK4 degradation and a favorable safety profile. It has initiated Phase 1 studies for KT-333 and KT-413 with clear INDs. Kymera's cash balance at year-end was approximately $568 million, ensuring operational funding into 2025. Notable milestones include the expected IND filing for KT-253 in 2H22 and ongoing partnerships to enhance its discovery platform.
Kymera Therapeutics (NASDAQ: KYMR), based in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company specializing in targeted protein degradation. The company will participate in several upcoming virtual investor conferences, featuring key executives discussing advancements in their drug discovery platform. Notable events include a fireside chat at the B. Riley Securities Oncology Investor Conference on January 28 and a panel on the promise of protein degradation at the BIO CEO and Investor Conference on February 16. Archived webcasts will be available on their website.
Kymera Therapeutics (NASDAQ: KYMR) has appointed Dr. John Maraganore to its Board of Directors, bringing extensive experience as the founding CEO of Alnylam Pharmaceuticals. Dr. Maraganore is recognized for his leadership in RNA therapeutics, having built Alnylam into a $25 billion company. He expressed excitement about Kymera's innovative approach to targeted protein degradation, highlighting its unique pipeline and commitment to advancing new therapeutic programs across immune-inflammatory and oncology indications. Kymera aims to become a leader in the emerging field of degrader medicines.